Abstract library

2266 results for "Large cell neuroendocrine cancer".
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells
Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ponni Balasundaram
#2861 Targeted Next Generation Sequencing Analysis Reveals the Genetic Characteristics of Gastric Neuroendocrine Neoplasmas
Introduction: there are abundant information about the clinical therapy and pathological features of gastric neuroendocrine neoplasms (gNENs) but little about its genetic characteristics.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Chen Huang
#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers
Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Ulrich M. Lauer
#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board
Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Fabrice Viol
Authors: Viol F, Sipos B, Amin T, Fahl M, ...
#2980 Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors
Introduction: The circadian clock genes encode transcription factors whose interaction with nuclear receptors allows the regulation of cellular metabolism.The invalidation of the genes of the clock core is associated with the development of many endocrine diseases including neuroendocrine cancer. Recently, the family of transcriptional coactivators PGC-1a has been identified as a key element in the integration of cellular metabolic state with the circadian clock. PRC, as a member of the PGC-1 family, was able to interact with several transcription factors, including the CLOCK factor. The specific induction of this PRC factor by the cell cycle, to modulate the energy function, the MAPkinase pathway and the expression of microRNAs, makes it a key factor in the metabolic adaptation of cancer cells.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Pr Frederique Savagner
Authors: Savagner F, Le Pennec S, ...
#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dijie Liu
#3035 Large-Cell Neuroendocrine Carcinoma of the Lung in Elderly Patient: Case Report and Review of Literature
Introduction: Lung neuroendocrine tumors account for less than 25% of lung cancers.Which is a rare malignant tumor with an aggressive profile has often already affected lymph nodes at presentation and it is de novo metastatic in nearly 40% of cases.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Hanane Aliane
Authors: Aliane H, Ghomari S, ...
#3089 Mixed Large and Small Cell Neuroendocrine Carcinoma of the Endometrium: A Case Report and Literature Review
Introduction: Neuroendocrine carcinoma (NEC) is an extremely rare subtype of endometrial cancer which is usually seen among perimenopausal or postmenopausal women. It runs an aggressive course and posts a clinical challenge due to limited treatment options available.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mary Anne Cruz
Authors: Cruz M A, Uyboco J, ...
#2986 Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: DVM Tiago B Gaspar